Compare · MDLN vs NVRO
MDLN vs NVRO
Side-by-side comparison of Medline Inc. (MDLN) and Nevro Corp. (NVRO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and NVRO operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.03B, about 22.3x NVRO ($2.15B).
- MDLN has hit the wire 22 times in the past 4 weeks while NVRO has been quiet.
- Both have 25 recent analyst ratings on file.
- Company
- Medline Inc.
- Nevro Corp.
- Price
- $36.53-0.75%
- $5.84+0.00%
- Market cap
- $48.03B
- $2.15B
- 1M return
- -15.81%
- -
- 1Y return
- -10.36%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- 2014
- News (4w)
- 22
- 0
- Recent ratings
- 25
- 25
Nevro Corp.
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. In addition, the company provides HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.
Latest MDLN
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)
- SEC Form 424B4 filed by Medline Inc.
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. disposed of 18,156,867 units of Class B Common Stock and converted options into 18,156,867 shares (SEC Form 4)
- SEC Form EFFECT filed by Medline Inc.
- Medline Inc. announces pricing of upsized secondary offering of Class A common stock
Latest NVRO
- SEC Form 15-12G filed by Nevro Corp.
- SEC Form EFFECT filed by Nevro Corp.
- Amendment: SEC Form SCHEDULE 13D/A filed by Nevro Corp.
- Director Mccormick Shawn returned 46,035 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Kosaraju Sridhar returned 46,575 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Grossman D Keith returned 228,552 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SVP, Chief Financial Officer Macleod Roderick H. returned 350,663 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Demane Michael F returned 503,618 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Karros Kirt P returned 17,452 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Oboyle Kevin C returned 43,396 shares to the company, closing all direct ownership in the company (SEC Form 4)